MAPT and Alzheimer disease: Accumulating evidence shows that the clearance of extracellular pathological tau forms, which represents the rationale for the promising results of the ongoing tau-based immunotherapy, is an actual AD therapeutic alternative to the not-encouraging Aβ-based pharmacological and immunological approaches [4, 5].